# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Acute Myeloid Leukemia, Adult

Acute Myelogenous Leukemia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 103 results.
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Feb 05, 2019
First Received: Apr 24, 2017
Disease(s): Relapsed Adult Acute Myeloid Leukemia, Refractory Adult Acute Myeloid Leukemia
Intervention(s): Merestinib, LY2874455
Locations: Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy
Status: Recruiting
Last Changed: Apr 20, 2018
First Received: Apr 17, 2018
Disease(s): Acute Myeloid Leukemia
Locations: National Taiwan University Hospital, Taipei, Taiwan
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
Status: Recruiting
Last Changed: Oct 07, 2016
First Received: May 04, 2015
Disease(s): Acute Myeloid Leukemia
Intervention(s): Daunorubicin, Cytarabine
Locations: Treatment and Diagnosis Center of Leukemia, Tianjin, Tianjin, China
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Status: Recruiting
Last Changed: Jun 14, 2017
First Received: Apr 14, 2017
Disease(s): Adult Acute Myeloid Leukemia
Intervention(s): CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
Locations: Fengtai District, Beijing Shi, China
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Status: Recruiting
Last Changed: Dec 03, 2018
First Received: Apr 26, 2013
Disease(s): Adult Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia
Intervention(s): PF-04449913
Locations: University of Colorado Cancer Center, Aurora, Colorado, United States
Ohio State University, Columbus, Ohio, United States
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Oct 01, 2018
First Received: Oct 21, 2015
Disease(s): Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Intervention(s): Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Locations: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Dec 20, 2018
First Received: Jul 18, 2016
Disease(s): Untreated Adult Acute Myeloid Leukemia
Intervention(s): Cytarabine, Daunorubicin Hydrochloride, Selinexor
Locations: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Status: Not yet recruiting
Last Changed: Sep 14, 2017
First Received: Sep 14, 2017
Disease(s): Adult Acute Myeloid Leukemia
Intervention(s): Cd11b and Cd56 markers
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Status: Recruiting
Last Changed: Apr 25, 2017
First Received: Jan 13, 2017
Disease(s): AML
Intervention(s): Daunomycin and Cytarabine (DA Regimen), Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)
Locations: Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Lentivirally Redirected CD123 Autologous T Cells in AML
Status: Recruiting
Last Changed: Dec 10, 2018
First Received: Dec 06, 2018
Disease(s): Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Refractory
Intervention(s): CART123 cells; cyclophosphamide; fludarabine
Locations: University of Pennsylvania, Philadelphia, Pennsylvania, United States